Services Overview

We act as your agent, representative, interim or mentor/coach. We can set up your company in Japan. We are dedicated to making your commercial success real!

We supply the market intelligence you need to be successful in Japan!

We connect you with the right Japanese companies within Biopharma, ATMP, CGT, Regenerative Medicine, Pharmaceuticals, Combination Devices, IVD’s, Universities and distributors. The right mix you need among: Trade Shows, KOLs, customers, partners, distributors . . .

A handshake under the Rising Sun of Japan.

Biosector = Commercialization in Japan

Preparation and reports – What you need to know!

We produce your feasibility studies and all other types of reports that you need to unlock your commercial pathway into Japan’s Pharmaceutical Industry. We help pave every step of your commercialization process.

Download for free:

You need: fast, accurate and actionable reports, feasibility studies, target lists and analysis to be able to draw up the best strategies.

We supply: just that!

By partnering with Biosector, you get the upper hand!

Market Entry: Seamless Integration and Strategic Positioning

Your success in Japan requires the following keys:

  1. Budget
  2. Cultural competence
  3. Clear goals
  4. Strategic approach
  5. Feet on the ground
  6. Long term mindset
  7. Patience
  8. Consistency


We make sure you are moving as fast as possible and that your expectations are aligned with those of your future clients and partners’ in Japan.

Market Expansion: Optimizing Your New Commercial Opportunities and Accelerating Growth

Expanding your footprint in Japan is crucial. Accelerating your growth successfully equals long-term success. You need competence and excellence: we supply! You need to optimize your new avenues for growth – we support you! We assist you in making sure of your new market segments and their strategies.

Leveraging your opportunities through our extensive industry connections is a valuable shortcut.

With Biosector, you have the advantage that only comes with exceptional professionals. Every step of the way.

About Stefan Sandström 

CEO of Biosector Ltd. Residence

Residence: Based in Metropolitan Tokyo since 2007.

Unique Perspective: Science and business.

Education: Medicine and chemical engineering.

Leadership: Successfully led multiple industrial companies as CEO.

Accreditations: Accredited business consultant via  German RKW.

Collaborations: Japanese partner to notable entities:  SPECTARIS and Kalms Consulting.

Recognitions: Appointed as an expert on conducting business in Japan by the EU-Japan Centre for Industrial Cooperation.

Track Record: Three decades of experience in international and cross-border business development, achieving first sales.

Passion: Kendo (martial art) with the rank of 6 dan.

Testimonials/Cases

Dan Spacie

CEO of MAP Patient Access, UK

”I have worked with Stefan Sandström outside of Biosector for over a year and will continue to work with him in Biosector. This is an exceptionally highly skilled partner, walking the extra mile and having made all the difference for building our traction in Japan.”

Anne-Kathrin Schmalz

Senior Manager Foreign Trade and Export Promotion

”Mr Sandström delivered an amazing seminar for our members in Sep 2021. He combined extensive specialist knowledge of the Japanese bio and laboratory market and how to bridge cultural differences. ”

Tony White

“Biosector’s business intelligence has helped me identify investment opportunities I would never have discovered. They deliver incisive analysis applying the Pareto Principle, allowing me to make fast decisions and save huge amounts of time. A great help for guiding the next steps forward.” – Tony White, founder of BioPhorum and angel investor

Blog

Wide abstract illustration of a value bridge supported by pillars for quality, transparency, accountability, and dignity, with red shortcut fragments falling away.
H&M invented a new kind of shrinkflation, taking the size of male underwear down. L suddenly meant M and a few years later: XL suddenly became L. I will never buy from them ever again. (And no, it wasn’t me who widened. I have kept old […]
Abstract wide illustration showing Japan drug pricing from listing to post-launch revisions, using blue shapes on a sand background with red trigger markers.
On December 12, 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) tabled a draft outline for the FY2026 drug pricing reform at Chuikyo’s drug pricing forum. The document reads like a set of engineering changes: small edits to formulas, clearer labels for existing schemes, and […]
Photorealistic scene of a consultant in a Tokyo meeting room connecting a foreign company with Japanese pharma executives.
You fly in, you present, you charm the room. Heads nod. The technical team likes your data. The business unit agrees that the fit is strong. Someone says, “Let’s stay in touch.” Then nothing. You follow up for months, sometimes years. You receive kind replies, seasonal […]
Abstract flat illustration of Japanese blockbuster drugs falling off a 2026 PMP price cliff with coloured bars and icons for key therapy areas.
Japan’s pharmaceutical market is about to run a high-stakes experiment in how hard a mature health system can lean on originator products while still claiming to reward innovation. The 2026 regular price revision does much more than trim National Health Insurance (NHI) prices. It crystallises a […]
Abstract illustration of Toronto’s biomedical innovation cluster centered on MaRS, research institutes, and startups.
Something quietly extraordinary has been happening in the heart of downtown Toronto. Within one of the most compact geographies of scientific activity in North America, a high-functioning biomedical innovation engine has been built. This engine, powered by world-class research output, startup formation, and translational medicine, isn’t […]
Selfie on the BioJapan 2025 exhibition floor: attendee in foreground, crowded aisles with posters and company booths, “AIST” jacket visible, signage directing to partnering zones.
The surge I sensed at BioJapan 2025 in October reflects deliberate engineering rather than hype: targeted co-investment programs, data-use reforms that enable real-world evidence, and mature clusters designed for translational speed. The following field guide expands on policy mechanisms, capital formation patterns, and build-site decisions, then […]

Please feel warmly welcome to contact us:

email: info@biosector.jp
phone: +81 80-3404-8431

Address: Yokohama Landmark Tower, 20th Floor, 2-2-1 Minatomirai, Nishi-ku, 〒220-8120,

Yokohama, JAPAN

Deliveries: Kosugaya 1-20-6-202, Sakae-ku, 〒247-0007, Yokohama, JAPAN